Why the Brain Doesn't Fight Back Against Vyvanse

Why don’t drugs like SSRIs and Vyvanse lose their effect over time, even though the brain fights to maintain chemical balance? This episode unpacks the elegant neuroscience behind two very different strategies. For SSRIs, the brain’s adaptation *is* the treatment—a two-to-four-week process of desensitizing inhibitory autoreceptors. For Vyvanse, the trick is pharmacokinetic stealth: a slow, gradual rise in dopamine that sneaks past the brain’s rate-of-change sensors. We explore prodrug design, tonic vs. phasic dopamine signaling, and why the prefrontal cortex responds differently than the striatum.